Skip to main content
Caplight Logo









OncoSenX

OncoSenX

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.oncosenx.com/

Last Round

VC Round

Aug 5, 2021

Total Funding Raised

$5.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

OncoSenX is a biotechnology company that develops transient gene therapies designed to treat cancer. The company's therapy delivers a program that induces apoptosis in cancerous cells using a plasmid DNA delivered with a proteo-lipid vehicle that selectively kills cancerous cells based on their transcriptional activity.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

gene therapysolid tumor therapylipid nanoparticleLNPcancer gene therapyoncology therapeuticsnon-viral deliveryDNA plasmiddrug delivery systemtranscriptional targetingProteo-Lipid VehiclePLVpreclinical biotechnologyprogrammable therapeuticsapoptosis induction

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OncoSenX Comparables

Compare OncoSenX with similar companies based on industry and business-model similarity.

OncoSenX comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Oisín Biotechnologies
79%
Entos Pharmaceuticals
76%
BreezeBio
68%

OncoSenX Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundAug 5, 2021
Series AApr 1, 2020
Pre SeedJul 8, 2019
SeedMar 14, 2019

Key People

Founding team and executive leadership

Matthew Scholz

Chief Executive Officer

Executive Team

Eric Garcia

Chief Operating Officer

Executive Team

OncoSenX Investors

Notable investors and investment history

OncoSenX investors
InvestorRounds
Helios CapitalVC Round
AltheaPre Seed
Methuselah FoundationVC Round, Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 33% MoM.

  • May 18, 2026

    Monthly visitors increased 105% MoM.

OncoSenX Filings

Explore SEC and related filing metadata, where available.

OncoSenX filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about OncoSenX's valuation, stock price, and market status.

Is OncoSenX a public or private company?

OncoSenX is a private company.

What is the current stock price of OncoSenX?

OncoSenX is a private company with no public stock price. No recent secondary market data is available.

How much is OncoSenX worth (valuation)?

Valuation information for OncoSenX is not publicly available.

Can I buy OncoSenX stock?

OncoSenX shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was OncoSenX's last funding round?

OncoSenX's most recent funding round was VC Round on August 5, 2021.

Who are the main investors in OncoSenX?

Key investors in OncoSenX include Methuselah Foundation.

Will OncoSenX IPO soon?

No public IPO plans have been announced for OncoSenX.

How can I track OncoSenX secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor OncoSenX's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range8
Year Founded2017
Last FundingAug 5, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?